title: Advanced prostate cancer: what's new in hormonal manipulation?
abstract: Prostate cancer is the second most common cause of male cancer deaths in the UK. It is one of the few hormone-sensitive cancers and androgen ablation produces subjective and objective tumour regression in 70-80% of patients for a variable period. Orchidectomy remains the gold standard for treatment although there is an increasing number of equally effective medical alternatives.
authors.affiliation: Department of Urology, Southmead Hospital, Bristol.
authors.forename: S F
authors.initials: SF
authors.lastname: Brewster
authors.forename: D A
authors.initials: DA
authors.lastname: Gillatt
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D009919:Orchiectomy; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012725:Sexual Behavior / Q000187:drug effects; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone